Alemtuzumab: clinical use
Evidence-based neurology checklist on alemtuzumab: clinical use: Mode of action Alemtuzumab is a humanised anti-CD52 monoclonal antibody It targets circulating memory cells It depletes CD52+ B lymphocytes: especially CD4, natural killer, and B cells Dosing Benefits in MS
Mode of action
- Alemtuzumab is a humanised anti-CD52 monoclonal antibody
- It targets circulating memory cells
- It depletes CD52+ B lymphocytes: especially CD4, natural killer, and B cells
Dosing
Benefits in MS
References
- Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis–a review of approved medications. Eur J Neurol 2016; 23(Suppl 1):18-27.
- Rice CM. Disease modification in multiple sclerosis: an update. Pract Neurol 2014; 14:6-13.
- Thomas K, Eisele J, Rodriguez-Leal FA, Hainke U, Ziemssen T. Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm 2016; 3:e228.
- Dargahi N, Katsara M, Tselios T, et al. Multiple sclerosis: immunopathology and treatment update. Brain Sci 2017; 7(7) pii: E78.
